AstraZeneca on Saturday announced it was acquiring Alexion Pharmaceuticals for $39 billion, a deal aimed at boosting AstraZeneca's immunology and rare-disease research, combining the companies ...

Alexion, AstraZeneca and certain of their directors, executive officers and employees may be deemed participants in the solicitation of proxies from Alexion shareholders in connection with the ...

Alexion has routinely featured among lists of top biopharma takeover prospects in the last couple of years, and that was a good call – AstraZeneca has just swooped in with $39 billion cash-and ...

Leading Covid-19 vaccine developer AstraZeneca agreed on Saturday to buy Boston pharmaceutical firm Alexion (ALXN) for $39 billion. The acquisition is one of the largest deals of the year for the ...

Alexion Pharmaceuticals, Inc.ALXN entered into a definitive agreement with U.K.-based pharmaceutical company, AstraZeneca plc AZN, whereby the latter will acquire the former.. Per the terms ...

Drugmaker AstraZeneca has agreed to buy US biotechnology group Alexion in a $39bn deal, marking the biggest agreement struck by a pharmaceutical company since the start of the Covid-19 pandemic.

AstraZeneca (AZN-0.67%) hopes to soon close its planned acquisition of Alexion Pharmaceuticals . The only hurdle left to jump is obtaining approval from United Kingdom regulators.

Alexion, AstraZeneca Rare Disease, today announced that it has entered a definitive agreement to acquire Lexington, Mass.-based LogicBio® Therapeutics ...

AstraZeneca Alexion Pharmaceuticals rare diseases blood diseases. For years, Alexion has been the only name in the game for a blood disease called paroxysmal nocturnal hemoglobinuria (PNH).

AstraZeneca's Alexion Pharmaceuticals was sued in Massachusetts federal court on Wednesday in a class action complaint alleging it misused its patents to extend its monopoly on its blockbuster ...

Alexion, AstraZeneca Rare Disease, today announced that it has entered a definitive agreement to acquire Lexington, Mass.- based LogicBio ® Therapeutics, Inc., a pioneering genomic medicine company.